Genmab A/S (GMAB) Competitors

Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Which has preferable earnings & valuation, GMAB or TAK?

Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$2.39B	7.80	$631.91M	$1.20	23.50
Takeda Pharmaceutical	$28.20B	1.50	$994.06M	$0.55	24.27

Does the media refer more to GMAB or TAK?

In the previous week, Takeda Pharmaceutical had 2 more articles in the media than Genmab A/S. MarketBeat recorded 7 mentions for Takeda Pharmaceutical and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.76 beat Takeda Pharmaceutical's score of 0.18 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, GMAB or TAK?

Genmab A/S has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Takeda Pharmaceutical has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

Do analysts recommend GMAB or TAK?

Genmab A/S currently has a consensus price target of $48.50, suggesting a potential upside of 71.99%. Takeda Pharmaceutical has a consensus price target of $14.00, suggesting a potential upside of 4.87%. Given Genmab A/S's higher possible upside, equities analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	3 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.38
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Does the MarketBeat Community favor GMAB or TAK?

Genmab A/S received 43 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 60.85% of users gave Genmab A/S an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 143 60.85%	Underperform Votes 92 39.15%
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%

Do insiders & institutionals have more ownership in GMAB or TAK?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Is GMAB or TAK more profitable?

Genmab A/S has a net margin of 30.74% compared to Takeda Pharmaceutical's net margin of 6.18%. Genmab A/S's return on equity of 18.90% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	30.74%	18.90%	16.83%
Takeda Pharmaceutical	6.18%	9.92%	4.71%

Summary

Genmab A/S beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.